tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MRUS Stock Latest News

Cautious Optimism: Hold Rating on Merus Amid Promising Yet Inconclusive Phase II Data for Petosemtamab
RatingsCautious Optimism: Hold Rating on Merus Amid Promising Yet Inconclusive Phase II Data for Petosemtamab
2d ago
MRUS
Cautious Hold Rating on Merus: Promising Efficacy in CRC Amidst Limited Data
PremiumRatings
Cautious Hold Rating on Merus: Promising Efficacy in CRC Amidst Limited Data
2d ago
MRUS
Merus to present interim data on petosemtamab at AACR-NCI-EORTC conference
PremiumThe Fly
Merus to present interim data on petosemtamab at AACR-NCI-EORTC conference
2d ago
MRUS
Cautious Optimism for Merus’s Petosemtamab in mCRC Amidst Limited Data, Hold Rating Maintained
PremiumRatings
Cautious Optimism for Merus’s Petosemtamab in mCRC Amidst Limited Data, Hold Rating Maintained
11d ago
MRUS
Oppenheimer positive on CytomX after Merus colon cancer data
PremiumThe Fly
Oppenheimer positive on CytomX after Merus colon cancer data
12d ago
CTMX
MRUS
Hold Rating on Merus’s Petosemtamab: Awaiting More Data for Colorectal Cancer Efficacy
PremiumRatingsHold Rating on Merus’s Petosemtamab: Awaiting More Data for Colorectal Cancer Efficacy
12d ago
MRUS
Merus announces initial interim data from phase 2 trial of petosemtamab
Premium
The Fly
Merus announces initial interim data from phase 2 trial of petosemtamab
12d ago
MRUS
Cautious Optimism: Hold Rating on Merus Amid Anticipation of Phase II Data Presentation and Genmab Acquisition
Premium
Ratings
Cautious Optimism: Hold Rating on Merus Amid Anticipation of Phase II Data Presentation and Genmab Acquisition
13d ago
MRUS
Genmab price target raised to $49 from $46 at Truist
PremiumThe Fly
Genmab price target raised to $49 from $46 at Truist
20d ago
GMAB
MRUS
Merus downgraded to Market Perform from Outperform at Leerink
PremiumThe Fly
Merus downgraded to Market Perform from Outperform at Leerink
20d ago
MRUS
Unusually active option classes on open October 2nd
PremiumThe Fly
Unusually active option classes on open October 2nd
24d ago
VG
CAN
Balanced Hold Rating Amid Genmab’s Acquisition of Merus and Anticipated CRC Data
PremiumRatings
Balanced Hold Rating Amid Genmab’s Acquisition of Merus and Anticipated CRC Data
26d ago
MRUS
Hold Rating on Genmab’s Acquisition of Merus Reflects Fair Valuation and Limited Upside Potential
PremiumRatingsHold Rating on Genmab’s Acquisition of Merus Reflects Fair Valuation and Limited Upside Potential
26d ago
MRUS
Merus downgraded to Neutral from Buy at UBS
Premium
The Fly
Merus downgraded to Neutral from Buy at UBS
26d ago
MRUS
Merus downgraded to Market Perform from Outperform at BMO Capital
Premium
The Fly
Merus downgraded to Market Perform from Outperform at BMO Capital
26d ago
MRUS
Merus downgraded to Equal Weight from Overweight at Barclays
PremiumThe Fly
Merus downgraded to Equal Weight from Overweight at Barclays
26d ago
MRUS
Merus downgraded to Market Perform from Outperform at LifeSci Capital
PremiumThe Fly
Merus downgraded to Market Perform from Outperform at LifeSci Capital
26d ago
MRUS
Balanced Hold Rating on Genmab’s Acquisition of Merus Amid Valuation and Strategic Fit Concerns
PremiumRatings
Balanced Hold Rating on Genmab’s Acquisition of Merus Amid Valuation and Strategic Fit Concerns
26d ago
MRUS
Merus downgraded to Neutral from Buy at Guggenheim
PremiumThe Fly
Merus downgraded to Neutral from Buy at Guggenheim
27d ago
MRUS
Hold Rating Given to Merus Amid Genmab Acquisition Reflecting Full Stock Valuation and Strategic Asset Integration
PremiumRatingsHold Rating Given to Merus Amid Genmab Acquisition Reflecting Full Stock Valuation and Strategic Asset Integration
27d ago
MRUS
Merus downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Merus downgraded to Neutral from Buy at H.C. Wainwright
27d ago
MRUS
Genmab price target raised to $34 from $32 at Leerink
Premium
The Fly
Genmab price target raised to $34 from $32 at Leerink
27d ago
GMAB
MRUS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >